Table 5.
Tumour volumetry in the left lobe in patients who underwent portal vein embolization (PVE) with and without bevacizumab (bev)
| Bev (n = 47) | Non-bev (n = 42) | P-value | |
|---|---|---|---|
| Tumour volume, cm3, median (range) | |||
| Pre-PVE | 0 (0–3.3) | 0 (0–2.6) | 0.435 |
| Post-PVE | 0 (0–5.2) | 0 (0–5.6) | 0.654 |
| P-value | 0.123 | 0.021 | |
| Change in tumour volumea, % (range) | 30.1 (− 62.4 to 190.6) | 54.3 (− 23.9 to 100.1) | 0.612 |
a
Change in tumour volumes in the left lobe, expressed as a percentage, in patients who did and did not receive bevacizumab (all received PVE).